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Abstract: Systemic capillary leak syndrome (SCLS) is a rare disease characterized by shock caused
by capillary hyperpermeability. The disease can occur in cancer patients and effective therapeutic
strategies have not been established yet. The aim of the study was to analyze the clinical and
laboratory data, treatment modalities, and mortality rate of patients and to identify contributing
factors leading to mortality of SCLS in cancer. We searched MEDLINE (inception to July 2018)
and of 4612 articles, we identified 62 case reports on SCLS associated with cancer or cancer-related
drugs in a total of 53 articles. SCLS was associated with cancer itself in 43.6%, with anti-cancer
agents in 51.6% and bone marrow transplantation (BMT) in 4.8%. Among anti-cancer agents,
granulocyte-colony stimulating factor (G-CSF) was the most frequently associated drug (14.6%),
followed by interleukin (IL)-2 (11.4%). The most common associated malignancies were hematologic
(61.3%) with non-Hodgkin lymphoma (22.7%) and multiple myeloma (12.9%) being the leading
causes. Common symptoms and signs included dyspnea (27.4%), edema (67.7%), hypotension (32.2%),
pleural effusion (29.0%), ascites (22.7%), oliguria (22.7%), and weight gain (21.0%). Patients with SCLS
were treated with steroids (59.7%), volume replacement (33.8%), diuretics (24.2%), inotropes (9.6%),
methylxanthines (12.8%), β2 agonists (4.8%), while intravenous immunoglobulins (IVIG) were
administered in 2 patients (3.2%) only. Among sixteen deaths during follow-up, four were directly
attributed to SCLS. Hematologic malignancies were associated with an increased risk for mortality
(hazard ratio (HR) 8.820, 95% confidence interval (CI) 1.126–69.063, p = 0.038). Taken together,
SCLS can be one important adverse event in cancer patients and careful monitoring of fluid volume
is required in the management of SCLS.
Keywords: systemic capillary leak syndrome; cancer; interleukin-2; steroids; intravenous
immunoglobulins
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1. Introduction
Systemic capillary leak syndrome (SCLS), also named vascular leak syndrome (VLS) or Clarkson
disease/syndrome, was first reported by Clarkson et al. in 1960 [1]. Clarkson et al. described idiopathic
SCLS as a rare disease of reversible plasma extravasation and vascular collapse accompanied by a
classic triad of hypoalbuminemia, hemoconcentration and hypotension in the absence of secondary
causes of shock [1]. Since then, more than 250 cases of idiopathic SCLS have been reported in the
literature and the number of cases increased by more recognition of this disease [2–5]. SCLS may be
idiopathic but can also be caused by other potential factors encountered in a clinical setting, such as
drugs, infections, or surgery [4]. Although not fully investigated yet, SCLS can also develop in patients
with cancer.
SCLS is a potentially fatal syndrome, since a high mortality rate was reported due to severe
shock [2,3,5]. According to the European Clarkson disease (EurêClark) registry data [6], 5- and 10-year
survival rates were 78% (n = 35) and 69% (n = 17), respectively, in the 65 patients with follow-up.
Nevertheless, clinical characteristics, treatments, and outcomes, including mortality rate, have not
yet been systemically studied in cancer patients. It is speculated that the non-specific nature of the
presenting signs and symptoms of SCLS may have resulted in considerable underdiagnosis despite
its high mortality rate. Furthermore, as there are presently no definitive guidelines for the initial and
long-term management of SCLS, it is also important to gain more insight into the efficacy of various
therapeutic approaches currently used.
In this special situation, many clinicians may not recognize SCLS, which can lead to a delay in the
diagnosis and treatment of SCLS, which increases mortality and morbidity. Therefore, there is a need
for early and reliable diagnosis of SCLS. The aim of this work was to extend the understanding of SCLS
in cancer patients. As no systematic review has been performed investigating the characteristics of
cancer patients with SCLS yet, we comprehensively analyzed the clinical and laboratory characteristics,
treatment patterns and patient survival in all published cases. Our data may give insight into the
clinical course, outcome, and potential therapeutic approaches of cancer-associated SCLS.
2. Methods
2.1. Literature Search and Study Selection
For this systematic review, we followed the guideline of Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) checklist (Supplementary Table S1). We performed a literature
search to systematically collect case reports of SCLS associated with cancer or cancer-related drugs.
Two investigators (K.H.L. and I.R.L.) independently searched PubMed and EMBASE and performed
an extraction of the data. The last search was done on 15th July 2018. The search terms were:
“(Capillary leak OR Vascular leak) AND (cancer OR carcinoma OR neoplasm OR tumor)”. We labeled
all articles by examining titles, abstracts, full texts in order and any discrepancy was discussed and
resolved by consensus between 3 investigators (J.I.S., K.H.L. and I.R.L.).
To determine the eligibility for inclusion in the review, we screened abstracts according to the
following criteria: (1) case reports of patients with cancer; and (2) SCLS was attributed to cancer itself
or cancer treatment-related drugs. Cases of SCLS which were caused by idiopathic forms, infection,
or surgery were excluded from this systematic review.
Our initial search yielded 4612 articles, but we finally identified 62 case reports in 53 articles that
met the inclusion criteria for this systematic review.
2.2. Data Extraction
For each eligible case report, we abstracted and recorded information on the name of authors,
journal name, publication year/month, age, gender, type of cancer, anti-cancer drugs or agents used,
clinical presentations at onset of SCLS, laboratory findings, types of treatment and outcome
(alive or death).
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2.3. Analyses of Case Reports
We presented the data as frequency for age, gender, type of cancer, anti-cancer agents used,
clinical presentation at onset of SCLS, laboratory findings, and types of treatment in tabulated form.
The data for each study are presented in Supplementary Table S2. We compared the clinical and
laboratory characteristics between being alive or dead during follow-up.
2.4. Statistical Analysis
Statistical analyses were performed, using the SPSS for Windows (SPSS Inc., Chicago, IL, USA) and
MedCalc version 15.8 (MedCalc Software, Ostend, Belgium). To identify factors related to mortality in
cancer patients with SCLS, various factors (demographic, clinical, laboratory findings, and treatments)
were compared between patients who were still alive and those who died. Chi-square or Fisher
exact test was performed for the analysis for categorical variables (sex, cause of SCLS, diagnosis of
cancer (hematologic or non-hematologic malignancy), presence of hypotension, hypoalbuminemia,
leukocytosis and the use of steroid therapy) and the independent t test for continuous variables (age,
systolic or diastolic blood pressures, serum albumin levels, white blood cell (WBC) or platelet counts,
hemoglobin and hematocrit levels). We also performed cox proportional hazard regression to analyze
whether one or more covariates might be associated with mortality. Kaplan-Meier analysis using
the log rank test was used to test whether the survival of the patients was different according to the
clinical, laboratory and treatment characteristics with time. All differences were considered statistically
significant at a p value < 0.05.
3. Results
The detailed process of literature search is presented in Figure 1. We identified 62 case reports on
SCLS associated with cancer or anti-cancer agents. Patient data are summarized in Supplementary
Table S2. Baseline characteristics are presented in Table 1. Forty-six % of the patients were aged over
50 years, while 21% were pediatric cases. There was a male preponderance, since 64.5% of cases
were male. Sixty-one % of the patients had a hematologic malignancy, among which non-Hodgkin
lymphoma was the most frequent (Table 1). SCLS was associated with cancer itself in 43.6%, associated
with anti-cancer agents in 51.6% and occurred after bone marrow transplantation (BMT) in 4.8% of
the patients. Among anti-cancer agents, granulocyte-colony stimulating factor (G-CSF) was the most
frequent potentially causative drug (14.6%), followed by interleukin (IL)-2 (11.4%) (Table 2).
Table 1. Age, sex, and diagnosis of cancer patients with systemic capillary leak syndrome.
Variables Observed Number of Patients (%)among Total Number of Patients (n = 62)
Age (years)
<10 5 (8.1%)
10–19 8 (12.9%)
20–29 1 (1.6%)
30–39 8 (12.9%)
40–49 11 (17.7%)
50–59 12 (19.4%)
>60 17 (27.4%)
Sex
Male 40 (64.5%)
Female 22 (35.5%)
Diagnosis of cancer
Hematologic malignancy 38 (61.3%)
Hodgkin lymphoma 4 (6.5%)
Non-Hodgkin lymphoma 14 (22.7%)
Multiple myeloma 8 (12.9%)
Hemophagocytic lymphohistiocytosis 3 (4.8%)
J. Clin. Med. 2018, 7, 418 4 of 12
Table 1. Cont.
Variables Observed Number of Patients (%)among Total Number of Patients (n = 62)
Acute lymphoblastic leukemia 2 (3.2%)
Acute myeloid leukemia 1 (1.6%)
Chronic myelocytic leukemia 2 (3.2%)
Plasma cell leukemia 1 (1.6%)
Malignant lymphoma of tonsil 1 (1.6%)
Malignant lymphoma of cervical cord 1 (1.6%)
Fanconi anemia 1 (1.6%)
Non-hematologic malignancy 24 (38.7%)
Renal cell carcinoma 4 (6.5%)
Colorectal cancer 4 (6.5%)
Pancreatic cancer 3 (4.8%)
Hepatic carcinoma 2 (3.2%)
Non-small cell lung cancer 2 (3.2%)
Breast cancer 2 (3.2%)
Pituitary adenoma 1 (1.6%)
Primitive neuroectodermal tumor 1 (1.6%)
Distal common bile duct cancer 1 (1.6%)
Nasopharyngeal cancer 1 (1.6%)
Ovarian cystic teratoma 1 (1.6%)
Sarcoma 1 (1.6%)
Myxofibroma of maxilla 1 (1.6%)
Table 2. Etiologies of cancer patients with systemic capillary leak syndrome.
Variables Total Number of Patients (n = 62)Observed Number of Patients (%)
Cancer * 27 (43.6%)
BMT-related GVHD 3 (4.8%)
Anti-cancer agents 32 (51.6%)
G-CSF 9 (14.6%)
Interleukin-2 7 (11.4%)
Denileukin diftitox 2 (3.2%)
Gemcitabine 2 (3.2%)
MINE regimen 2 (3.2%)
Gemcitabine + paclitaxel 1 (1.6%)
Doxorubicin 1 (1.6%)
Bortezomib 1 (1.6%)
Clofarabine 1 (1.6%)
Cyclosporin A 1 (1.6%)
Trastuzumab 1 (1.6%)
Busulfan + etoposide + nimustine 1 (1.6%)
Pemetrexed 1 (1.6%)
Oxaliplatin 1 (1.6%)
Oxaliplatin + capecitabine 1 (1.6%)
BMT: Bone marrow transplantation, GVHD: Graft-versus-host disease, G-CSF: Granulocyte-colony stimulating
factor, MINE regimen: mitoguazone, ifosfamide, vinorelbine, etoposide. * “Cancer” refers to systemic
capillary leak syndrome cases only due to cancer itself, excluding other factors such as GVHD or induced by
chemotherapeutic agents.
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Figure 1. Flo chart of literature search.
Main presenting symptoms and findings using physical and radiological examination of patients
with SCLS included peripheral edema (67.7%), hypotension (32.2%), pleural effusion (29.0%),
dyspnea (27.4%), ascites (22.7%), oliguria (22.7%), weight gain (21.0%), fever (17.7%) and pulmonary
edema (11.3%) (Table 3). Laboratory findings showed that leukocytosis was observed in 40.1%,
anemia in 48.0%, hemoconcentration in 63.6%, thrombocytopenia in 73.7% and hypoalbuminemia in
96.9% of the patients (Table 4).
Patients with SCLS were treated with steroids (59.7%), volume replacement (33.8%), diuretics
(24.2%), inotropes (9.6%), methylxanthines (12.8%), β2 agonists (4.8%), intravenous immunoglobulins
(IVIG) (3.2%), chemotherapeutic or immunosuppressive agents (11.3%) and procedures including
dialysis or fluid drainage (8.0%) (Table 5). Twenty-nine % of patients with SCLS received a single
therapy including steroids (19.4%), volume replacement (6.4%) and methylxanthines (3.2%) while
33.9% received two kinds of therapy, and 22.6% received more than three kinds of therapy with various
combinations of the above mentioned therapies (Supplementary Table S3).
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Table 3. Clinical presentation of cancer patients with systemic capillary leak syndrome.
Clinical Presentation Observed Number of Patients (%)among Total Number of Patients (n = 62)
General condition
Edema 42 (67.7%)
Weight gain 13 (21.0%)
Malaise 5 (8.1%)
General weakness 3 (4.8%)
Skin rash 4 (6.4%)
Hot flushing 1 (1.6%)
Sweating 1 (1.6%)
Gum hypertrophy 1 (1.6%)
Weight loss 1 (1.6%)
Disturbance of consciousness 1 (1.6%)
Inflammation-related
Fever 11 (17.7%)
Lymph node enlargement 3 (4.8%)
Otalgia 1 (1.6%)
Pulmonary
Dyspnea 17 (27.4%)
Pleural effusion 18 (29.0%)
Pulmonary edema 7 (11.3%)
Tachypnea 5 (8.1%)
Hypoxemia 4 (6.4%)
Pulmonary hypertension 1 (1.6%)
Cardiovascular
Hypotension 20 (32.2%)
Hypertension 3 (4.8%)
Pericardial effusion 6 (9.7%)
Tachycardia 5 (8.1%)
Bradycardia 1 (1.6%)
Chest pain 1 (1.6%)
Syncope 1 (1.6%)
Decreased exercise tolerance 1 (1.6%)
Pericarditis 1 (1.6%)
Gastrointestinal
Ascites 14 (22.7%)
Nausea 3 (4.8%)
Vomiting 4 (6.4%)
Abdominal distention 3 (4.8%)
Diarrhea 2 (3.2%)
Hepatosplenomegaly 1 (1.6%)
Renal
Oliguria 14 (22.7%)
Proteinuria 1 (1.6%)
Neurologic
Dizziness 1 (1.6%)
Back discomfort 1 (1.6%)
Tremor 1 (1.6%)
Paresthesia 1 (1.6%)
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Table 4. Laboratory findings of cancer patients with systemic capillary leak syndrome.
Laboratory Findings Total Number of Patients (n = 62)Observed/Measured Number of Patients (%)
WBC count
Leukocytosis (>15,000/µL) 11/27 (40.1%)
Leukopenia (<4000/µL) 9/27 (33.3%)
Normal (4000–15,000/µL) 7/27 (25.9%)
No information 35/62 (56.4%)
Hemoglobin
Anemia (<12.0 g/dL) 12/25 (48.0%)
Polycythemia (>15.0 g/dL) 6/25 (24.0%)
Normal (12.0–15.0 g/dL) 7/25 (28.0%)
No information 37/62(60.0%)
Hematocrit
Hemoconcentration (Hct > 41%) 7/11 (63.6%)
Decreased hematocrit (Hct < 30%) 2/11 (18.2%)
Normal (Hct 30–41%) 2/11 (18.2%)
No information 51/62 (82.3%)
Platelet count
Thrombocytopenia (<150,000/µL) 14/19 (73.7%)
Normal (150,000–450,000/µL) 5/19 (26.3%)
No information 43/62 (69.4%)
Albumin
Very low (<2.5 g/dL) 16/32 (50.0%)
Low (2.5–3.5 g/dL) 15/32 (46.9%)
Normal (>3.5 g/dL) 1/32 (3.1%)
No information 30/62 (48.4%)
WBC: white blood cell, Hct: hematocrit.
Table 5. Treatment of cancer patients with systemic capillary leak syndrome.
Treatment Observed Number of Patients (%)among Total Number of Patients (n = 62)
Steroids 37 (59.7%)
Methylprednisolone 14 (22.7%)
Prednisolone 12 (19.4%)
Cortisone 4 (6.4%)
Hydrocortisone 3 (4.8%)
Dexamethasone 2 (3.2%)
Methylprednisolone→ prednisolone 1 (1.6%)
Other steroids 1 (1.6%)
Volume replacement 21 (33.8%)
Fluid resuscitation 4 (6.4%)
Crystalloid/colloid 2 (3.2%)
Transfusion * 1 (1.6%)
Albumin 11 (17.7%)
Hydroxyethyl starch 1 (1.6%)
Fluid resuscitation + albumin 1 (1.6%)
Fluid resuscitation + transfusion + albumin +
hydroxyethyl starch 1 (1.6%)
Diuretics 15 (24.2%)
Furosemide 6 (9.6%)
Other diuretics 9 (14.6%)
Inotropes 6 (9.6%)
Dopamine 1 (1.6%)
Norepinephrine 1 (1.6%)
Other vasopressors 4 (6.4%)
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Table 5. Cont.
Treatment Observed Number of Patients (%)among Total Number of Patients (n = 62)
Methylxanthines 8 (12.8%)
Theophylline 6 (9.6%)
Aminophylline 2 (3.2%)
β2 agonists 3 (4.8%)
Terbutaline 2 (3.2%)
Terbutaline + tulobuterol 1 (1.6%)
Intravenous immunoglobulins 2 (3.2%)
Chemotherapeutic or immunosuppressive agents † 7 (11.3%)
Cyclosporine A 2 (3.2%)
Cyclophosphamide 1 (1.6%)
Melphalan 1 (1.6%)
Chloraminophene 1 (1.6%)
Bevacizumab 1 (1.6%)
Cyclosporine A + cyclophosphamide + melphalan 1 (1.6%)
Other agents 6 (9.6%)
Antibiotics (cefepime + vancomycin) 1 (1.6%)
Antihistamine 1 (1.6%)
Leukotriene antagonist (Montelukast®) 1 (1.6%)
Serine protease inhibitor (Ulinastatin®) 1 (1.6%)
Radiosone 1 (1.6%)
Naftazone 1 (1.6%)
Procedure 5 (8.0%)
SLEDD 1 (1.6%)
CRRT 1 (1.6%)
Pericardial/thoracic/ascites drainage 2 (3.2%)
Plasma exchange 1 (1.6%)
SLEDD: Slow extended daily dialysis, CRRT: Continuous renal replacement therapy. * Transfusion contains only
blood-driven materials (e.g., packed red blood cell (RBC), platelet, or fresh frozen plasma (FFP)) except albumin.
† Only contained cases used for the treatment of systemic capillary leak syndrome, not for chemotherapy.
To identify factors associated with mortality of patients with SCLS, various factors (demographic,
clinical and laboratory features, and treatment) were compared between the 43 patients who recovered
and the 16 patients who died. Univariate analyses showed that there were no differences in age, sex,
cause of SCLS, diagnosis of cancer (hematologic or non-hematologic malignancy), systolic or diastolic
blood pressures, serum albumin levels, WBC or platelet counts, hemoglobin and hematocrit levels
and the use of steroid therapy (Supplementary Table S4). However, hematologic malignancies were
associated with an increased risk for mortality (hazard ratio (HR) 8.820, 95% confidence interval (CI)
1.126–69.063, p = 0.038) on univariate analysis (Table 6). Kaplan-Meier analysis demonstrated that
there were no differences in the survival rate between SCLS patients according to sex, decreased serum
albumin levels (<2.5 vs. >2.5 g/dL and <3.0 vs. >3.0 g/dL), hypotension, leukocytosis and the use of
steroid therapy (p > 0.05), but hematologic malignancies were associated with a decreased survival in
cancer patients with SCLS (p = 0.013) (Figure 2 and Supplementary Figure S1).
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Table 6. Factors associated with mortality in cancer patients with systemic capillary leak syndrome.
Variables
Univariate Cox Proportional Hazard Model
Hazard Ratio 95% CI p Value
Age 1.005 0.978 to 1.032 0.739
Sex 1.293 0.415 to 4.024 0.657
Hematologic 8.820 1.126 to 69.063 0.038
Cancer-induced 0.498 0.161 to 1.543 0.227
Drug-induced 2.455 0.794 to 7.591 0.119
SBP 1.012 0.945 to 1.085 0.728
DBP 1.371 0.452 to 4.16 0.578
Hypotension 1.235 0.36 to 4.244 0.737
Alb 1.379 0.417 to 4.558 0.598
Alb < 2.5 g/dL 3.878 0.402 to 37.423 0.241
Alb < 3.0 g/dL 1.687 0.17 to 16.773 0.655
WBC 1.000 1 to 1 0.352
WBC > 15,000/µL 0.022 0 to 2908.101 0.526
Hemoglobin 1.059 0.863 to 1.301 0.582
Platelet 1.000 1 to 1 0.600
Steroid 0.561 0.169 to 1.858 0.344
SBP: Systolic blood pressure, DBP: Diastolic blood pressure, Alb: Albumin, WBC: White blood cell count, CI:
confidence interval.
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Figure 2. Kaplan-Meier analysis showing there was a decreased survival rate in systemic capillary leak
syndrome patients with hematologic malignancies (p = 0.013).
The cause of death was documented in 13 of the 16 patients and in four was directly
associated with SCLS. Other causes included cancer relapse or disease progression (2 patients),
cardiac amyloidosis (1 patients), cardiac and hepatic amyloidosis (1 patient), sepsis (3 patients),
and pneumonia (1 patient) (Supplementary Table S5).
4. Discussion
Since Clarkson et al. first reported the phenomenon of SCLS [1], more than 250 cases have been
reported [3]. However, the exact incidence of SCLS is unclear and has not been described in idiopathic
or secondary forms. We believe that SCLS might have been underrecognized and underestimated in
the past because of its non-specific symptoms and signs which can be misdiagnosed as septic shock,
anaphylaxis or various kinds of angioedema such as episodic angioedema with eosinophilia syndrome
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(Gleich’s syndrome) and non-episodic angioedema with eosinophilia and nodules, eosinophilia,
rheumatism, dermatitis and swelling (NERDS) [7,8]. Considering the paucity of SCLS, the physician’s
awareness is essential to reduce the substantial morbidity and mortality associated with it and to
provide timely therapy [8].
In addition, it is important to improve knowledge about the pathophysiology, presenting
symptoms and signs, as well as appropriate diagnostic and therapeutic strategies. There have been
some reports on the beneficial effect of IVIG to treat idiopathic SCLS [5,6]. In contrast, limited evidence
is present regarding treatment possibilities in secondary SCLS.
Although no study has investigated soluble factors or diagnostic markers of cancer-related
SCLS, some pathogenic molecules have been investigated in idiopathic SCLS and these include;
(1) increased numbers of circulating CD25+ T cells and perivascular infiltrations of mononuclear cells
with an increased number of CD8+ T lymphocytes, suggesting T cell activation [9–11]; (2) endothelial
injury and apoptosis [12,13], (3) increased serum cytokine levels such as elevated serum chemokine
(C-X-C motif) ligand (CXCL)10, chemokine ligand 2 (CCL2), IL-1β, IL-6, IL-8, IL-12 and tumor necrosis
factor-α (TNF-α) [14,15] and (4) high levels of plasma vascular endothelial growth factor (VEGF) and
angiopoietin-2 [16]. However, few mechanisms have been suggested in the pathogenesis of SCLS
related to cancer or cancer-related drugs [17].
There have been scarce reports on SCLS associated with cancer or cancer treatment-related drugs
and no guidelines have been established on its management. Therefore, our study is the first to perform
a systematic analysis of all published case reports. Through documented case reports, we found that
SCLS can develop as a first manifestation of cancer or during cancer, after the use of several cancer
treatment-related drugs and after BMT. Therefore, clinicians should at least consider a differential
diagnosis of SCLS in cancer patients during initial presentation and disease course.
The clinical presentation of SCLS in cancer patients appears to be similar to that observed in
idiopathic forms, including edema, dyspnea, and ascites due to capillary leak, accompanied by
hypoalbuminemia, and hypotension due to hypovolemia. Signs such as fever (17.7%) and leukocytosis
(40.1%) suggest that inflammation might be one of the triggering factors. In most patients, there was
hypoalbuminemia, but one patient (3%) had a normal albumin level and thus developed capillary
leakage by another unknown mechanism. As expected, 63.6% of patients showed hemoconcentration.
Due to the rarity of SCLS, treatment strategies are mostly based on observational studies rather
than randomized controlled clinical trials. Furthermore, as the exact pathophysiology of idiopathic or
secondary SCLS is still largely unknown, the treatment of SCLS is mostly determined by empirical use
of several drugs. In idiopathic SCLS, volume replacement using intravenous albumin, crystalloids,
or colloids is recommended to treat acute episodes. It was suggested that the use of steroids cannot
prevent the acute episodes in most patients and may actually be deleterious to patients experiencing
more frequent attacks despite occasional success in some patients [2]. In our analysis, however,
steroids were used in 60% of the patients, which did not affect mortality and patient survival.
β2 agonists and theophylline have been used to prevent recurrences of idiopathic SCLS [2], but only a
small percent of patients received these agents in our systematic review. In addition, IVIG has been
used successfully in the treatment of idiopathic SCLS, but only two patients (3.2%) received IVIG
in cancer-associated SCLS. These results indicate that treatment patterns of SCLS in cancer patients
might differ from those used in idiopathic SCLS. There is a clear need to design clinical trials to
determine the therapeutic efficacy of steroids, IVIG, β2 agonists and other agents in the management
of cancer-associated SCLS, which will facilitate the establishment of treatment guidelines.
With respect to the prognosis of SCLS in cancer patients, we found that hematologic malignancies
were associated with an increased risk for mortality. There were no other demographic, clinical or
laboratory indicators to predict mortality in our analysis and the use of steroids did not affect the
outcome. Although death as outcome was observed in 16 of the 59 patients (27.1%) in our analysis,
death could be directly attributed to SCLS only in four of the 13 (30.8%) patients in which the cause of
death was documented.
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5. Conclusions
We analyzed the clinical and laboratory data, treatment patterns and patient survival in all
published cases with cancer-associated SCLS. However, our systematic review may have the limitation
of some missed case reports. Nevertheless, our data will give a relevant insight by promoting
knowledge about SCLS in cancer patients. The therapeutic role of IVIG which has been shown
to be effective in idiopathic CLS should also be evaluated in cancer-associated SCLS [18–20].
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/7/11/418/s1,
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syndrome, Figure S1: Kaplan-Meier analysis for survival rate in SCLS patients according to various variables.
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